| |
 |
Dr. David Yang, Ph.D.
Chief Executive Officer, MicroConstants China Inc.
Beijing, China |
|
| |
| Biography: |
|
| |
| David Yang has 20 years of research and management experience in the biopharmaceutical industry, including R&D, licensing, business development, and marketing in the United States, Singapore, and China. In 2007, David established MicroConstants China Inc to bring U.S. GLP/GCP quality system to China. Its PK lab in Beijing is the first such lab receiving OECD-GLP certification in China. His team has implemented ICH GCP quality system at several clinical trial centers in China, including the Phase I Unit of No. 307 hospital, which is qualified later by many MNC and Quintile. |
| |
| Prior to co-founding MicroConstants China, David Yang served as Consulting Director for ST Microelectronics' Lab-on-Chip program. Before joining ST Microelectronics, he was the General Manager for Biotech Investment at CIDC Group of Singapore. David has also held Senior Scientist positions at Collateral Therapeutics Inc. and Immusol Inc. in San Diego, California. David earned his bachelor’s degree in Biology from Fudan University in Shanghai, China, and his Ph.D. degree in Molecular Biology and Biochemistry from the University of Toledo Medical Center in Toledo, Ohio. |
| |
| Session: |
|
| |
| 21st November 2015 (Saturday) |
 |
13:00 – 14:40 |
|
| |
| Session III: Early Clinical Development in Asia |
| |
| |
| |
| |
| |
|
|
